- Report
- August 2022
Global
From €951EUR$990USD£817GBP
- Report
- February 2021
Global
From €2844EUR$2,960USD£2,442GBP
- Report
- September 2022
- 30 Pages
Global
From €3839EUR$3,995USD£3,295GBP
- Clinical Trials
- January 2022
- 419 Pages
Global
From €2402EUR$2,500USD£2,062GBP
- Clinical Trials
- November 2021
- 404 Pages
Global
From €2402EUR$2,500USD£2,062GBP
- Drug Pipelines
- July 2020
- 173 Pages
Global
From €1922EUR$2,000USD£1,650GBP
- Report
- May 2023
- 103 Pages
Global
From €3500EUR$3,902USD£3,110GBP
- Drug Pipelines
- March 2021
Global
From €1922EUR$2,000USD£1,650GBP
- Report
- December 2023
- 132 Pages
Global
From €913EUR$950USD£784GBP
- Report
- September 2022
- 300 Pages
Global
From €5852EUR$6,090USD£5,023GBP
- Report
- April 2023
- 160 Pages
Global
From €5764EUR$5,999USD£4,948GBP
- Report
- March 2022
- 149 Pages
Global
From €4324EUR$4,500USD£3,712GBP
The Autism Drug market is a subset of the Central Nervous System Drugs market, which includes drugs used to treat neurological disorders. Autism drugs are used to treat the core symptoms of autism spectrum disorder, such as impaired social interaction, communication difficulties, and repetitive behaviors. These drugs are typically prescribed in combination with behavioral therapies, and may include antipsychotics, antidepressants, and stimulants.
The Autism Drug market is highly competitive, with a range of pharmaceutical companies offering treatments. Some of the major players in the market include Eli Lilly, Johnson & Johnson, Pfizer, Novartis, and AbbVie. Other companies, such as Otsuka Pharmaceuticals, Sunovion Pharmaceuticals, and Merck, also offer treatments for autism spectrum disorder. Show Less Read more
